Tag

#GSK

Home » GSK

24 posts
Bookmark?Remove?

GSK pharma head flags need for speed in high-pressure drug market

LONDON (Reuters) – Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain’s largest drugmaker told Reuters. Luke Miels, who joined GSK in September 2017 after a contract... More »

Bookmark?Remove?

GlaxoSmithKline to look for early-stage assets: CEO

(Reuters) – GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said on Tuesday. Britain’s biggest drugmaker is also likely to evaluate licensing deals and would continue to inves... More »

Bookmark?Remove?

GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

LONDON (Reuters) – GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma Walmsley that unnerved investors. GSK has lagged rivals in recent years... More »

Bookmark?Remove?

FDA staff raises efficacy doubts on GSK’s lung disease treatment

(Reuters) – U.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plc’s drug Nucala in treating a disease that limits airflow to the lungs. Nucala, already approved for treating severe asthma patients, i... More »

Bookmark?Remove?

Clamor for GSK shingles shot points to bigger profits

LONDON (Reuters) – GlaxoSmithKline is facing “unprecedented” demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought. In the short term, though, GSK faces a problem. W... More »

Bookmark?Remove?

GSK slims portfolio with sale of rare disease gene therapy drugs

LONDON (Reuters) – GlaxoSmithKline is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker’s pharmaceuticals portfolio. Financially, the ... More »

Bookmark?Remove?

Big pharma turns to AI to speed drug discovery, GSK signs deal

FILE PHOTO: Signage for GlaxoSmithKline is seen on its offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new me... More »

Bookmark?Remove?

FDA, Mylan silence on generic Advair may be good news for GSK

Signage for GlaxoSmithKline is seen on it’s offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo A deadline for U.S. regulators to give a verdict on a generic copy of GlaxoSmithKline’s blockbuster inhaled lung drug Advair has passed wit... More »

Bookmark?Remove?

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

Emma Walmsley of GlaxoSmithKline poses in this undated photograph released in London on September 20, 2016. Courtesy of GlaxoSmithKline/Handout via REUTERS Emma Walmsley, GlaxoSmithKline’s (GSK.L) incoming CEO, will take over Britain’s biggest drugmaker at a c... More »

GlaxoSmithKline seeks U.S. approval for triple lung drug

Signage for GlaxoSmithKline is seen on it’s offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo GlaxoSmithKline said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the mark... More »

GSK seeks U.S. approval for shingles vaccine Shingrix

Signage for GlaxoSmithKline is seen on it’s offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo GlaxoSmithKline said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster ... More »

GSK sells anesthetics to Aspen for up to $370 million

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor/File Photo GlaxoSmithKline is to sell its portfolio of anesthetic drugs to South Africa’s Aspen Pharmacare for up to 280 million pounds ($372 million) as pa... More »

Europe gives green light to first gene therapy for children

LONDON The world’s first life-saving gene therapy for children, developed by Italian scientists and GlaxoSmithKline, has been recommended for approval in Europe, boosting the pioneering technology to fix faulty genes. The European Medicines Agency (EMA) said o... More »

GSK shuts U.S. plant due to bacteria, no supply disruption seen

Drugmaker GlaxoSmithKline temporarily closed a North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire’s disease. The Legionella bacteria were discovered during routine inspections at the site in Zebulon... More »